CD28 and neoplasm: Accordingly, simultaneous multiple interaction T-cell-engaging (SMITE) bispecific antibodies, comprising a combination of two BiTE antibodies, have been developed.85 In fact, T-cell co-stimulation with an anti-CD28 × anti-ROR1 BiTE was shown to enhance the anti-tumour activity of a CD3 ×  ROR1 BiTE in K562 cells transduced with ROR1.